Teicoplanin is a less toxic replacement for vancomycin in most situations where resistant organisms are encountered, and is therefore the drug of choice. As a commonly used drug in cardiac surgery, we treated a case of presumptive endocarditis with teicoplanin that caused neutropenic sepsis, unmasked on withdrawal of treatment.
WilsonAPGayaH. Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases. J Antimicrob Chemother1996; 38: 507–521.
2.
MartinoPVendittiMMicozziA. Teicoplanin in the treatment of Gram-positive-bacterial endocarditis. Antimicrobial Agents Chemother1989; 33: 1329–1334.
3.
LivorneseLLGoldMJohnsonCCMeasleyRKayeDKorzeniowskiO. Clinical evaluation of teicoplanin in the treatment of Gram-positive bacterial intravascular infections. J Antimicrob Chemother1993; 31: 188–191.
4.
DaveyPGWilliamsAH. A review of the safety profile of teicoplanin. J Antimicrob Chemother1991; 27(Suppl B): 69–73.
5.
WilsonAP. comparative safety of teicoplanin and vancomycin. Int J Antimicrob Agents1998; 10: 143–152.
6.
KwonHSChangYSJeongYYLeeSMSongWJKimHB. A case of hypersensitivity syndrome to both vancomycin and teicoplanin. J Korean Med Sci2006; 21: 1108–1110.
7.
PerrettCMMcBrideSR. Teicoplanin induced drug hypersensitivity syndrome. BMJ2004; 328: 1292–1292.
8.
MorrisAWardC. High incidence of vancomycin-associated leucopenia and neutropenia in a cardiothoracic surgical unit. J Infect1991; 22: 217–223.
